EMPLICITI® (elotuzumab) for injection, for intravenous use Initial U.S. Approval: INDICATIONS AND USAGE EMPLICITI is a SLAMF7-directed immunostimulatory antibody indicated in • combination with lenalidomide and dexamethasone for the treatment of adult. Identify the appropriate Medical Science Liaison in your area with just a few simple clicks. Empliciti (elotuzumab) Kyprolis (carfilzomib) Melphalan (Alkeran) Ninlaro (ixazomib) Pomalyst (pomalidomide) Revlimid (lenalidomide) Sarclisa (isatuximab-irfc) Thalomid (thalidomide) Velcade (bortezomib) Xpovio (selinexor) Using the Immune System to Fight Multiple Myeloma.

What is the status of Empliciti® (elotuzumab), the new immunotherapy?

]

Elotuzumab Injection; Eloxatin ® see Oxaliplatin Injection; Eltrombopag; Eluxadoline; Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir; Elyxyb ® see Celecoxib; Elzonris ® see Tagraxofusp-erzs Injection; Emagrin ® (as a combination product containing Aspirin, Caffeine, Salicylamide)see Aspirin; Emapalumab-lzsg Injection. Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial. Meletios A Dimopoulos, Paul G Richardson, Nizar J Bahlis, Sebastian Grosicki, Michele Cavo, Meral Beksaç, Wojciech Legieć, Anna M Liberati. Learn. Research. Collaborate. Begin your journey with Learn Immuno-Oncology. Test your knowledge and determine where to start.

Empliciti® (elotuzumab) is the first monoclonal antibody approved to treat multiple myeloma. It is given intravenously (into the vein, IV) and taken in. EMPLICITI® elotuzumab is indicated for the treatment of adult patients with multiple myeloma in combination with: REVLIMID® (lenalidomide) and dexamethasone. Elotuzumab, IgG1 antibody, targets signaling lymphocytic activation molecule F7 (SLAMF7), and induces myeloma cell death by activating natural killer cells. Elotuzumab is unique among the three new multiple myeloma treatments in the way it exerts its anticancer effects. It is a monoclonal antibody that attaches to a. May 13,  · Elotuzumab did not improve progression-free survival (PFS), overall survival (OS), or any other efficacy endpoint in this trial. These results were published in . May 09,  · Elotuzumab plus lenalidomide and dexamethasone did not significantly improve progression-free survival versus lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma who are ineligible for HSCT. Although these data contribute to the treatment landscape, further research is needed to find ways to improve treatments in the front . Elotuzumab (Empliciti®): a monoclonal antibody that targets the SLAMF7 pathway; approved for subsets of patients with advanced multiple myeloma Isatuximab (Sarclisa®): a monoclonal antibody that targets the CD38 pathway; approved for . Empliciti (elotuzumab) is a SLAMF7-directed immunostimulatory antibody. Empliciti is specifically indicated for use in combination with lenalidomide and. Elotuzumab. Adult Medication. Share. Print. This information from Lexicomp® explains what you need to know about this medication, including what it's used.

EMPLICITI safely and effectively. See full prescribing information for. EMPLICITI. EMPLICITI™ (elotuzumab) for injection, for intravenous use. ELOTUZUMAB (el oh tooz ue mab) is a monoclonal antibody. It is used to treat multiple myeloma. This medicine may be used for other purposes; ask your health. The portal for rare diseases and orphan drugs · Search for an orphan drug · Elotuzumab.

Elotuzumab - Empliciti (elotuzumab) Kyprolis (carfilzomib) Melphalan (Alkeran) Ninlaro (ixazomib) Pomalyst (pomalidomide) Revlimid (lenalidomide) Sarclisa (isatuximab-irfc) Thalomid (thalidomide) Velcade (bortezomib) Xpovio (selinexor) Using the Immune System to Fight Multiple Myeloma.

VIDEO

What Should we know about FDA approval of elotuzumab?